Vaxxinity (NASDAQ:VAXX) Lifted to Buy at Zacks Investment Re

Vaxxinity (NASDAQ:VAXX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Zacks.com reports. The brokerage currently has a $4.75 target price on the stock. Zacks Investment Research‘s price target points to a potential upside of 9.95% from the […]

Related Keywords

United States , Dallas , Texas , , Geode Capital Management , Securities Exchange Commission , Virtu Financial , Zacks Investment Research , Investment Advisers , United Biomedical Inc , Vaxxinity Company Profile Get Rating , Managers Group , Nasdaq , Vaxxinity Inc , Millennium Management , Get Rating , Investment Research , Exchange Commission , Capital Management , Company Profile , Lewy Body , Vaxxinity , Nasdaq Vaxx , Vaxx , Medical , Upgrade ,